Valuation: Virax Biolabs Group Limited

Capitalization 2.3M 1.98M 1.84M 1.71M 3.2M 208M 3.45M 21.2M 8.33M 99.32M 8.63M 8.45M 366M P/E ratio 2026 *
-0.78x
P/E ratio 2027 * -1.29x
Enterprise value 2.3M 1.98M 1.84M 1.71M 3.2M 208M 3.45M 21.2M 8.33M 99.32M 8.63M 8.45M 366M EV / Sales 2026 *
575x
EV / Sales 2027 * 575x
Free-Float
93.37%
Yield 2026 *
-
Yield 2027 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-9.36%
1 week-26.42%
Current month-10.35%
1 month-31.70%
3 months-52.36%
6 months-65.56%
Current year-10.35%
More quotes
1 week 0.3
Extreme 0.3032
0.4
1 month 0.3
Extreme 0.3032
0.51
Current year 0.3
Extreme 0.3032
0.44
1 year 0.3
Extreme 0.3032
2.46
3 years 0.3
Extreme 0.3032
16
5 years 0.3
Extreme 0.3032
290
10 years 0.3
Extreme 0.3032
290
More quotes
Manager TitleAgeSince
Chief Executive Officer 40 31/12/2012
Chief Operating Officer 61 31/08/2023
Director TitleAgeSince
Chairman 40 31/12/2012
Director/Board Member 51 -
Director/Board Member 61 -
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-9.36%-26.42%-86.97%-95.84% 2.3M
-0.92%+4.28%+2.98%+14.36% 49.13B
+0.29%+0.43%+18.05%+8.75% 41.14B
+5.11%+9.59%+90.16%+29.71% 38.85B
+3.27%+3.76%+25.05%+42.80% 32.74B
+2.37%+50.22%+181.77%+298.64% 23.19B
-26.23%-1.48%+24,147.39%+4,036.79% 16.09B
+1.54%-0.08%+72.84%+166.20% 17.14B
+1.98%+6.28%+49.19%+13.43% 15.04B
+1.74%-9.03%-15.92%-18.35% 14B
Average -2.34%+3.85%+2,448.45%+449.65% 24.73B
Weighted average by Cap. -0.36%+7.53%+1,616.34%+316.58%
See all sector performances

Financials

2026 *2027 *
Net sales 4K 3.44K 3.21K 2.98K 5.56K 361K 5.99K 36.85K 14.48K 173K 15K 14.69K 637K 4K 3.44K 3.21K 2.98K 5.56K 361K 5.99K 36.85K 14.48K 173K 15K 14.69K 637K
Net income -4.94M -4.25M -3.96M -3.68M -6.87M -446M -7.4M -45.53M -17.89M -213M -18.53M -18.15M -787M -5.2M -4.47M -4.17M -3.87M -7.22M -469M -7.79M -47.89M -18.82M -224M -19.49M -19.09M -827M
Net Debt - -
More financial data * Estimated data
Logo Virax Biolabs Group Limited
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Employees
19
More about the company
Date Price Change Volume
13/01/26 0.3100 $ -9.36% 279,385
12/01/26 0.3420 $ -5.52% 135,418
09/01/26 0.3620 $ -1.63% 71,310
08/01/26 0.3680 $ -9.14% 744,284
07/01/26 0.4050 $ -3.87% 555,307

Delayed Quote Nasdaq, January 13, 2026 at 09:00 pm

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3100USD
Average target price
1.000USD
Spread / Average Target
+222.58%
Consensus

Quarterly revenue - Rate of surprise